IBCSG 25-02: A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (TEXT).

Trial Profile

IBCSG 25-02: A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (TEXT).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Exemestane (Primary) ; Tamoxifen; Triptorelin
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms TEXT
  • Most Recent Events

    • 01 Sep 2017 Results (n=1872) of exploratory analysis of TEXT and SOFT studies, published in the Annals of Oncology.
    • 13 Mar 2017 According to an Ipsen media release, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, in coordination with fourteen other European regulatory agencies, has approved Decapeptyl as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy. The approval was based on results from SOFT and TEXT trials.
    • 29 Jun 2016 This trial was completed in Germany, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top